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Methods. A total of 364 patients were randomly assigned to receive either fluvastatin 40 mg or placebo in combination with conventional cyclosporine-based immunosuppressive therapy.
HMG-CoA (3,hydroxy, 3-methylglutaryl coenzyme A)
The primary end point was treated first acute rejection. Secondreductase inhibitor (statin) therapy is of proven benefit ary end points included biopsy-proven rejection, histological sein reducing cardiovascular morbidity and mortality in verity of rejection, occurrence of steroid-resistant rejection, and serum creatinine at three months following transplantapatients with or without coronary disease (CVD) [1] [2] [3] [4] [5] [6] . tion.
However, there is some evidence that certain effects of Results. Fluvastatin was well tolerated; no patients developed these drugs, including beneficial effects in patients with myositis or rhabdomyolysis. There was no difference in the osteoporosis [7] [8] [9] [10] , are independent of cholesterol reacute rejection rate [86 (47.3%) fluvastatin vs. 87 (47.8%) pladuction and may be due to the reduced synthesis of other cebo] and no significant difference in the severity of rejection, steroid resistant rejection or mean serum creatinine at three isoprenoid products of the mevalonate pathway [7, 8] .
months (160 mol/L vs. 160 mol/L). Total cholesterol, lowThe putative potential effects on osteoporosis, however, density lipoprotein (LDL) and high-density lipoprotein (HDL) have recently been challenged [11] . Four pilot studies cholesterol and triglyceride levels increased following renal have examined the effects of statin treatment in solid transplantation. With the exception of the increase in HDL-C, organ transplant populations. In kidney recipients a sigwhich was augmented, the increases in lipid parameters were significantly reduced by fluvastatin (total cholesterol ϩ17.5% nificant reduction in the rejection rate was observed [12] .
vs. 35.7%; LDL-C ϩ6.3% vs. 46.7%; HDL-C ϩ43.3% vs.
Two studies in heart transplant recipients have reported 38.1%; triglyceride ϩ52.2% vs 77.6%).
conflicting results. Wencke et al could not demonstrate
Conclusions. Contrary to the reported effects of statins, fluany significant effect on rejection rates in a four-year follow-up study [13] . In the study of Kobashigawa et al, an effect was only evident for severe rejections with including simvastatin in one arm, failed to demonstrate any effect of simvastatin on acute renal allograft rejec- 2001 by the International Society of Nephrology tion (Kasiske et al, Transplantation 69:S225, 2000) . Studused. The use of antibody therapy, mycophenolate or tacrolimus was precluded at the outset, although subseies in experimental animals also have shown prolongation of islet and cardiac allograft survival associated with quent changes in therapy for clinical indications, such as acute rejection, were at the discretion of the investigating statin treatment [15, 16] . The explanation for these observations has focused on the effects of statins on the funcphysician. The protocol was approved by the national and local ethical committees in the participating centers tion of leukocytes and the observation that inhibition of the production of specific isoprenoids-farnesyl and in Norway, Sweden, Finland, United Kingdom and Ireland. The study was carried out according to the Declarageranylgeranyl-might inhibit proliferation of T lymphocytes and natural killer (NK) cells in vitro [7, [17] [18] [19] [20] . tion of Helsinki. All patients gave written informed consent to participate, and were recruited prior to, or within Recently, it has been demonstrated that statins might inhibit the inducible expression of the class II major 48 hours of transplantation surgery. histocompatibility complex and thus repress activation Study design of T cells in the immune response [21] . Preliminary findings in human transplant recipients suggest that statins Fluvastatin, 40 mg per day (or placebo), was administered in a double-blind fashion for twelve weeks followmay also reduce NK cell function in vivo [12, 14, 15] . Taken together, while these studies suggest a potential ing transplantation. Blood samples were taken for fasting lipids, serum creatinine and full blood count at recruitmechanism for statin-mediated immunosuppression, in the absence of adequately powered studies, it remains ment and 2, 6 and 12 weeks after commencement of therapy. A central laboratory (Medinet, Breda, The Nethuncertain whether this effect is of any clinical relevance.
Hyperlipidemia is common in renal transplant recipierlands) was assigned to analyze all serum lipids and selective biochemical parameters. ents (RTR), with levels of cholesterol and triglyceride increasing in the early post-transplant period, and is
The primary end point was treated acute rejection, defined as a clinically suspected acute rejection episode, likely to contribute to increased cardiovascular risk [22, 23, 24] . Thus, there is considerable interest in the use of during which the patient completed a course of highdose steroids according to the local protocol. There were statins in this population. Fluvastatin has potential benefits in the treatment of hyperlipidemia in organ transno stipulations on the treatment either for subsequent rejection episodes, or for changes in immunosuppressive plantation [25, 26, 27] and it does not share a metabolic pathway with the calcineurin inhibitors cyclosporine and therapy deemed appropriate following the first acute rejection episode. The study protocol required biopsy tacrolimus. Inhibition of the microsomal enzyme cytochrome P450 3A4 (CyP 3A4) by these immunosuppresconfirmation where possible. All biopsies were scored by an experienced renal histopathologist according to the sive agents inhibits the metabolism of statins. The increase in fluvastatin concentration by calcineurin inhibitors is Banff criteria [28] . In addition to the primary end point, secondary end points were studied. These included biopsytherefore less than that observed with other statins. Thus, the present study was designed to assess the effects proven rejection, histological severity of rejection, the number of steroid resistant rejection episodes, graft loss, of administration of fluvastatin on acute rejection in RTR receiving cyclosporine-based immunosuppressive serum creatinine at three months, absolute lipid levels, and lipid sub-fractions. Sequentially numbered sets of study regimes.
medication were made available to each clinical site. Each medication pack was labeled with a study identifi-METHODS cation code and randomization number. Randomization Patients was stratified by center and blocked pseudorandomization was performed by the producer centrally (SwitzerThis study was an international, multicenter, randomized, double-blind, placebo controlled trial of fluvastatin land). The block size was eight patients. Following randomization, patients were assigned a unique patient 40 mg daily or matched placebo in RTR. All patients aged 18 years or older, receiving cadaveric or living reidentifier consisting of a center number and a patient number. Center numbers were assigned centrally and lated renal allografts, were eligible. Multiorgan transplant recipients were excluded, but patients receiving a patient numbers by the investigator. Patients received medication according to randomization number: patients second or subsequent renal allograft were eligible for inclusion. The protocol also excluded patients with mawith a cadaveric donor graft were assigned the next available randomization number starting from the beginning, lignant disease, serological evidence of HIV or HbsAg, systemic infection, pregnancy, or those using inadequate patients with a living donor graft were assigned the next available number starting from the end of the list of contraceptive measures. All patients received cyclosporine-based immunosuppressive regimes, including preavailable randomized numbers. All study personnel directly involved in the conduct of the study were blinded dnisolone with, or without, azathioprine. There were no stipulations on the dosages of immunosuppressive agents to treatment until all patients had completed the study and all data were finalized. Randomization was centrally Eighty-three percent of the patients who commenced the study completed the full protocol, with no difference performed using a validated system that automates the random assignment of treatment groups to randomizabetween groups. The reasons for withdrawal, including seven deaths, are outlined in Table 2 , and did not differ tion numbers. Randomization data were kept strictly confidential, accessible only to authorized persons, until between groups. the time of unblinding.
Efficacy analysis Statistical analysis
Acute rejection. In the intention-to-treat analysis, 86 (47.3%) patients had a treated acute rejection episode The planned sample size was based on the assumption that fluvastatin would reduce the incidence of first-treated compared with 87 (47.8%) in the placebo group (P ϭ 0.92; Table 3 ). There was no difference in the mean time rejection episodes by 30%, from 45% in the placebo group to 31.5% in the fluvastatin-treated group. Fourto first acute rejection [19 (17) vs. 18 (12) days]. The first rejection episode was biopsy-confirmed in 70 and 75 hundred-and-four patients were required without adjustments for drop outs, with 5% alpha level and power ϭ patients, respectively, and was deemed steroid resistant (necessitating change to, or addition of, second-line im-80%. Due to administrative reasons, the trial was stopped when 364 randomized and evaluable patients were communosuppression) in 38 (20.9%) patients in the fluvastatin group and 34 (18.7%) in the placebo group (P ϭ pleted. With this number we could detect a 31.5% relative reduction in incidence, still with 80% power. The 0.44). Eighteen patients (9.9%) in the fluvastatin group, and 19 (10.4%) in the placebo group (P ϭ 0.86) experiprimary efficacy analyses were based on intention-totreat for all variables. All patients who received at least enced a second acute rejection episode. The corresponding numbers of graft losses (including death with a funcone dose of study medication were included. Per protocol analyses also were performed for those patients who tioning graft) were 12 and 7, respectively (P ϭ 0.33).
The spectrum of histological severity is shown in Table 3 . completed the trial on study medication. Descriptive statistics are given as mean (SD) for continuous variables There was a trend towards a smaller number of biopsies with mild rejection in the fluvastatin group, although and number of cases (%) for the categorized variables. The Chi-square or Fisher exact tests were used to comthis failed to achieve statistical significance (P ϭ 0.09). Finally, there was no difference in graft function at three pare such variables between the two treatment groups. The Cochran-Mantel-Haenzel test was used to compare months following transplantation. The serum creatinine was 160 Ϯ 62 mol/L in the fluvastatin group and 160 Ϯ categorical variables.
The primary end point comparison was a pre-planned 83 mol/L in the placebo group, in those patients whose grafts continued to function at this time point. test for the difference between the Kaplan-Meier estimates of not having a primary event within three months Lipid levels. It is well established that levels of total cholesterol TC, low-density lipoprotein-cholesterol (LDL-C) in the two treatment groups. Comparison of changes in the lipid values between baseline and three-month visits and high-density lipoprotein-cholesterol (HDL-C) rise following transplantation as a result of immunosuppreswas done by calculating the mean of individual absolute and percentage differences with confidence limits.
sive therapy and altered diet [22] [23] [24] . Thus, the effects of statins must be viewed against the changing background. The absolute levels of TC, LDL-C, triglycerides (TG) RESULTS and HDL-C are shown in Table 4 , and the mean values Study population for LDL-cholesterol throughout the study period in Figure 1. There was a 17.5 (11.5 to 23.4)% increase (mean, A total of 364 patients (260 males) were recruited between January 1998 and June 1999 in 11 centers in four 95% confidence interval) in total cholesterol in the fluvastatin group, compared with 35.7 (28.7 to 42.8)% inEuropean countries (147 UK, 97 Norway, 68 Sweden, 40 Finland, 12 Ireland). Eighty-seven patients received crease in the controls. The final total cholesterol at 12 weeks was 10.0% lower in the active treatment group. living donor transplants and 277 cadaveric transplants. Demographic data are shown in Table 1 . The mean age LDL-C showed a similar pattern. There was a 6.3 (Ϫ0.09, 12.7)% increase in the fluvastatin group and a 46.7 (29.0, was 48.4 (14.1) years, 92.6% of patients were of Caucasian origin and 12% had diabetes. The mean time on 64.5)% increase in the placebo group with the final LDL-C being 18.2 lower in the active treatment group. renal replacement therapy was around three years, and 8% of patients had previously received a renal trans-HDL-C also increased following transplantation; the increase in the treatment group was 43.3 (34.8 to 51.9)% plant. There was no difference in any of these parameters between the two groups. The pattern of primary renal versus 38.1 (29.6 to 46.6)% in the control group. At 12 weeks the HDL-C was 6.1% higher in the active treatdisease, cytomegalovirus (CMV) status, donor age, cold ischaemia and cross-match information also was similar ment group. Triglyceride levels were higher following transplantation with a trend towards a smaller increase (Table 1) . cal course in the early post-transplant period (Table 5) . Abbreviations are: TC, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; TG, triglycerides. 
DISCUSSION
This is the first study of adequate power to address results demonstrate that whilst fluvastatin 40 mg per day is effective in reducing total cholesterol and LDL-C, the drug has no effect on the acute rejection rate, severity of rejection or graft function during the first three months There were no differences between treatment groups after renal transplantation. and, specifically, there were no episodes of rhabdomyoThe study design was based on the results of two studlysis. There were 16 reports of an elevation of creatinine ies in heart [13, 14] and one pilot study in renal [12] kinase (CK) levels to more than five times the upper transplant recipients. The renal study showed a marked limit of normal, nine in the fluvastatin and seven in the reduction (57%) in rejection episodes [12] . Of the two placebo group, respectively. There were also 31 reported heart transplant studies, one showed no significant effect increases in transaminase levels to more than three times on rejection rates [13] , and the other only an effect on the upper limit of normal, 11 of which were in the fluvasevere, but not mild-to-moderate rejection episodes or statin group. These biochemical abnormalities required the overall rejection rate [14] . While the results of the cessation of therapy in some cases. However, the number two studies indicating an effect suggest that statins may of discontinuations due to drug-related side effects was have a role in preventing acute rejection in solid organ similar in both groups.
transplantation [12, 14] , the studies were small and only Basal immunosuppression. There were no differences one was designed to assess rejection rates [12] . Indeed, between groups for cyclosporine A (CsA), prednisolone none of the studies were adequately powered to detect or azathioprine dose throughout the study (Table 6) . a significant reduction in this end point. There are numBlood pressure. Blood pressure values were similar in ber of possible explanations for the discrepancy between both groups. At 12 weeks the mean systolic blood presthe result of our study and those previously published. sure was 145 Ϯ 18 versus 146 Ϯ 19 mm Hg (fluvastatin First, the published studies may be spuriously positive vs. placebo, P ϭ 0.33) and the diastolic blood pressure due to small sample size and the differences reported showed a similar pattern (85 Ϯ 11 vs. 86 Ϯ 13 mm Hg) .
may reflect other aspects of the study design or patient Mean weight also showed no difference between groups, population. Second, the dose of fluvastatin used may not be comparable to the doses of pravastatin used in 76.0 Ϯ 11.5 vs. 74 Ϯ 12.9 kg at 12 weeks. previous studies. Finally, it is clearly possible that immupresent and previous studies [12] [13] [14] . Although cyclosporine interacts with the metabolism of fluvastatin, the area nosuppressive actions are not common to all statins (fluvastatin, simvastatin), but specific to certain drugs of that under the curve for fluvastatin is increased only about twofold during cyclosporine therapy [26] . In contrast, class (pravastatin).
concomitant cyclosporine increases the area under the Study size and design curve several-fold for other statins [27] . The results of this study confirm the predicted beneficial effects on The single-center report by Katznelson et al in 48 renal transplant patients, half were randomized to pravastatin the lipid profile in the post-transplant period. However, these data are difficult to compare with outcome studies 20 mg treatment [12] . The study did not have adequate statistical power to detect a reduction in rejection epiof statin therapy in the general population because of the pattern of increasing levels of total cholesterol, sodes, and the very high rejection rate in the placebo group (58%) suggests that this was not a representative LDL-C, and HDL-C and triglycerides that follow transplantation. The key findings, based on the intention-tostudy population. In contrast, the acute rejection rate in our study is similar to that reported in other studies using treat analysis, show that LDL-C was 40.5% lower in the fluvastatin group, compared with 26.3% [13] and 26.4% conventional cyclosporine-based double or triple therapy. Moreover, although the number of rejection episodes [14] in the studies in cardiac transplantation and 27.8% in the pilot study in renal transplant recipients [12] in (6 vs. 14) was significant at a 5% level in the study of Katznelson et al [12] , had a single additional rejection which beneficial effects on acute rejection were reported. The comparison with other published studies is limited episode occurred in the active treatment group (7 vs. 13) the findings would not have achieved statistical signifiby the fact that previous studies reported the time-averaged lipid levels during the follow-up period and these cance. Thus, the failure of our present study, which has greater statistical power to detect a reduction in acute are likely to decrease with reduction in immunosuppressive therapy beyond three months, Thus, overall, fluvasrejection rates, to confirm the earlier report in kidney transplant recipients is likely to reflect the small size in tatin appears to have had a similar effect on LDL-C to that observed in the other studies and the achieved level the previous report.
The reported study of cardiac transplant recipients demof mean LDL-C of around 3.1 mmol/L was similar to that reported in the previous studies (2.8 to 3.0 mmol/L; onstrating a significant reduction in rejections included fewer than 100 patients [14] . The improvement in rejec- [12] [13] [14] ). Other lipid parameters also were modified by active treatment. HDL-C was 5.2% higher, total cholestion in this study was confined to severe, or hemodynamically significant, rejection episodes with no effect on mild, terol was 18.3% lower and triglyceride 25.4% lower in the fluvastatin group at three months post-transplant. moderate or focal moderate rejection episodes. Furthermore, it was designed to study regression of accelerated Moreover, the efficacy of fluvastatin in the present study is diluted by the patients who failed to take therapy graft vascular disease (GVD) and not the incidence of rejection episodes. However, the authors demonstrated a for the three-month follow-up period ( Table 2 ). The achieved levels of TC, HDL-C and TG show a similar significant reduction in intimal proliferation in the statin treatment group in accordance with the study of Wenke pattern in comparison with other studies and are slightly less than those reported for this dose of fluvastatin in et al [13] . Cardiac allograft rejection is more likely to have hemodynamic sequelae in the presence of severe carefully controlled single-center studies in stable renal transplant recipients [25, 27] . Thus, it seems unlikely a GVD and thus, the non-immunological effects of statins on GVD, rather than any immunosuppressive effects may higher dose would have unmasked a significant effect on rejection when none was apparent in the presence of a offer an explanation for the effects on rejection severity and patient survival. significant benefit on plasma lipids.
Is immunosuppression unique to other statins? Statin type and dosage
The choice of statin and dose equivalence may offer In vitro and in vivo studies have shown a variety of effects of statins that appear to be mediated by intermealternative explanations for the discrepancy between the
